On Wednesday, KeyBanc Capital Markets maintained its Overweight rating on Recursion Pharmaceuticals (NASDAQ:RXRX) with a steady price target of $12.00. The affirmation follows Recursion's recent business update after the completion of its acquisition of Exscientia. The merger combines Recursion's scaled biology exploration with Exscientia's precision chemistry design and automated small molecule synthesis, enhancing the company's drug discovery and development capabilities.
Recursion, now integrated with Exscientia's technologies, boasts a robust pipeline with over 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs. These programs, mainly targeting oncology, rare diseases, and other areas with significant unmet medical needs, could potentially each achieve annual peak sales of over $1 billion. The company anticipates approximately 10 clinical program milestones within the next 18 months, including data readouts, preliminary data updates, regulatory submissions, and trial initiations.
Financially, Recursion has already secured approximately $450 million through upfront and milestone payments. With its current partnerships and pipeline, the company has the opportunity to earn up to an estimated $20 billion in future payments. Recursion's strategy involves focusing on complex therapeutic areas that command substantial financial investment or offer competitive advantages, while also leveraging partner expertise and clinical development resources.
Finally, Recursion's approach to data strategy includes licensing specific data subsets and key tools, as well as generating new data in-house. This dual method aims to maximize the value drivers for its pipeline and partnerships. The recent adjustments in estimates by KeyBanc have been attributed to Recursion's third-quarter 2024 results and the updated outlook provided by the company.
In other recent news, Recursion Pharmaceuticals received stockholder approval for its acquisition of Exscientia plc. The company also launched a new model, OpenPhenom-S/16, to enhance drug discovery processes. This model is now accessible in the Vertex (NASDAQ:VRTX) AI Model Garden on Google (NASDAQ:GOOGL) Cloud. Recursion has also received FDA clearance for a Phase 1/2 clinical trial of REC-1245, a potential treatment for solid tumors and lymphoma.
KeyBanc Capital Markets maintained its Overweight rating for Recursion following the FDA approval. In addition, Recursion announced a $30 million deal with Genentech and plans for a $200 million public offering of Class A common stock. The company has also secured support from Evotec SE for its proposed acquisition of UK-based Exscientia plc.
Recursion has seen changes in leadership, with Dr. Robert Hershberg appointed as the new Chair of the Board, and Dr. Najat Khan stepping in as the new Chief R&D Officer and Chief Commercial Officer.
InvestingPro Insights
Recursion Pharmaceuticals' recent business update and acquisition of Exscientia have positioned the company for potential growth, but current financial metrics reveal some challenges. According to InvestingPro data, Recursion's revenue for the last twelve months as of Q3 2024 was $65.18 million, with a significant revenue growth of 147.62% in Q3 2024. This aligns with the company's robust pipeline and potential for future earnings mentioned in the article.
However, InvestingPro Tips highlight that Recursion is "quickly burning through cash" and "not profitable over the last twelve months." This is reflected in the company's operating income margin of -606.35% for the same period. These figures underscore the importance of the $450 million in upfront and milestone payments and the potential for up to $20 billion in future payments mentioned in the article.
Despite these challenges, two InvestingPro Tips offer positive insights: "2 analysts have revised their earnings upwards for the upcoming period" and "Liquid assets exceed short term obligations." These points suggest some optimism about Recursion's financial future, which could be linked to the expanded capabilities and pipeline following the Exscientia acquisition.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Recursion Pharmaceuticals, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.